To make things easier, leave this box checked On shared devices, we recommend that you disconnect from Euroquity when you are done
Email

You will receive an email to define a new password

Location

Select your country

and your language

Hi ,

Welcome to your personnel profile page! Fill in your information in order to become more visible to organizations that interest you.

% completed

%

Company

Rius Medical

Rius Medical_logo
8
EQ SCORE

The EQ Score shows the company's activity and appeal on the platform: profile completeness, news, likes, follows, membership in one or more labels or communities, number of members in its network, etc.

Rius Medical mission is to make its proprietary highly innovative platform available at 3 years to pharmaceutical and biotech partners - Proprietary cell lines for drug delivery. Engineer stem cells for next generation therapeutics as core business.

Waldachtal, Baden-Württemberg, Germany

Send a message

English

Rius Medical

English

Cell & Gene Therapy will shape the future of medicine, when novel technologies proceed beyond the primary goals of safety and efficacy. Uneconomical manufacturing is an industry challenge and represents a major roadblock to the sustainable commercialisation of cellular products. 

The solution, Rius Medical technology engineers stem cells into therapeutic products. Offering a Business-to-Business solution to U.S. based company Rubius Therapeutics and France-based Erytech...

See more

Cell & Gene Therapy will shape the future of medicine, when novel technologies proceed beyond the primary goals of safety and efficacy. Uneconomical manufacturing is an industry challenge and represents a major roadblock to the sustainable commercialisation of cellular products. 

The solution, Rius Medical technology engineers stem cells into therapeutic products. Offering a Business-to-Business solution to U.S. based company Rubius Therapeutics and France-based Erytech Pharma for upgraded red blood cells that do more than simply carry oxygen. For example Erytech Pharma’s therapeutic product is Phase III approved for Acute Lymphoblastic Leukemia and Phase II approved for Pancreatic Cancer.

Rius Medical is seeking a 30.000 euro financing such as a Convertible Loan of 30.000 euro, at a discounted rate of 0,50 euro per share, to help bridge the 2-3 months time for medifundo to bring 300.000 euro equity capital if not 600.000 euro.

Rius Medical implements innovation targeting Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes, all within one platform technology! 

Beyond providing solutions for global healthcare’s biggest cost drivers, an EXIT opportunity at 3 years for early investors joining this Series A investment round of up to 1 million euro and pre-money valuation at 4 million euro will result in EUR 54 million financial benefit for FIVE products or EUR 10,5 million financial benefit for TWO products at 3 years to early investors.

  • 1

    Followers

Our latest news

Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent

Communities

ESIL - Early Stage Investing Launchpad
Early Stage Investing Launchpad has the overall objective of developing and boosting the activities for Business Angels through an international capacity building program
391 Members
InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
428 Members

Our history

Start in 31 August 2016

  • 31 August 2016

    registration with the commercial register of Stuttgart local court under folio HRB 757947

to be continued ...